Preprint · OA
via OpenAlex
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres, Mads D.M. Engelmann, G. Kees Hovingh, Milana Ivkovic, Larry Lo, Douglas Kling, Pablo E. Pérgola, Dominic S. Raj, Peter Libby, Michael Davidson
The Lancet · 2021 · ▲ 688 citations
Abstract
This phase 2 double-blind, randomised, placebo-controlled trial published in The Lancet in 2021 examines IL-6 inhibition with ziltivekimab.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/s0140-6736(21)00520-1
- Canonical
- link ↗
- Fetched
- 2026-07-28 MST
Cite this
APA
Ridker, P.M., Devalaraja, M., Baeres, F.M., Engelmann, M.D., Hovingh, G.K., Ivkovic, M., Lo, L., Kling, D., Pérgola, P.E., Raj, D.S., Libby, P., & Davidson, M. (2021). IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. <em>The Lancet</em>. https://doi.org/10.1016/s0140-6736(21)00520-1
Vancouver
Ridker PM, Devalaraja M, Baeres FM, Engelmann MD, Hovingh GK, Ivkovic M, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. 2021. doi:10.1016/s0140-6736(21)00520-1.
BibTeX
@unpublished{paul2021ILinhi,
title = {IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial},
author = {Paul M. Ridker and Matt Devalaraja and Florian M.M. Baeres and Mads D.M. Engelmann and G. Kees Hovingh and Milana Ivkovic and Larry Lo and Douglas Kling and Pablo E. Pérgola and Dominic S. Raj and Peter Libby and Michael Davidson},
journal = {The Lancet},
year = {2021},
doi = {10.1016/s0140-6736(21)00520-1},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
ENCell 2027
Open access · US-GOV
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of EN001 in Patients With Sarcopenia
Longeveron Inc. 2017
Open access · US-GOV
A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty
Treeway B.V. 2023
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
Pardis Specialized Wellness Institute 2020
Open access · US-GOV
The Effect of Intradialytic Exercise on Dialysis Patients' Survival: A Randomized Controlled Trial
Free Radical Biology and Medicine 2021
Preprint · OA
Cell cycle re-entry and arrest in G2/M phase induces senescence and fibrosis in Fuchs Endothelial Corneal Dystrophy
Panacela Labs LLC 2016
Open access · US-GOV